Close
Nordic 9Nordic 9

Avant Bio (investor - Venture Capital)

United States
See something wrong or missing? Let us know
Offices:New York

Avant Bio is an American invstor doing early stage and growth equity investments in Life Sciences, TechBio, Healthtech and Diagnostics.

Average round investment:8.46M USD
Average number per year:1.0
Distribution: 2025 (1)2024 (1)
Portfolio companies: France AbbeLightGermany PL Biosciences
Mostly invests in: France France (1) Biotech (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Avant Bio

Name Criteria
Germany Peppermint Venture Partners
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Austria Square One Foods
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Poland Adamed
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Jacques Lewiner
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland VP Venture Partners
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Bruker
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany The Vantage Value GmbH
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Essential Capital
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France MGEN
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
China LePure Biotech
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top